# A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

> **NCT00382213** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 210 (—)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** Olmesartan medoxomil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00382213
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** —
- **Final completion:** 2004-12
- **Target enrollment:** 210 (—)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00382213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00382213, "A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00382213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*